14 results on '"Tabada, Grace"'
Search Results
2. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population.
- Author
-
Rana, Jamal S., Tabada, Grace H., Solomon, Matthew D., Lo, Joan C., Jaffe, Marc G., Sung, Sue Hee, Ballantyne, Christie M., and Go, Alan S.
- Subjects
- *
ATHEROSCLEROSIS risk factors , *CARDIOVASCULAR diseases , *ATHEROSCLEROSIS , *SOCIODEMOGRAPHIC factors , *COHORT analysis , *PATIENTS , *CORONARY heart disease prevention , *ANTILIPEMIC agents , *STROKE prevention , *CORONARY disease , *DIABETES , *LONGITUDINAL method , *LOW density lipoproteins , *MYOCARDIAL infarction , *POPULATION , *PREVENTIVE health services , *RESEARCH funding , *RISK assessment , *STROKE , *PREVENTION - Abstract
Background: The accuracy of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Risk Equation for atherosclerotic cardiovascular disease (ASCVD) events in contemporary and ethnically diverse populations is not well understood.Objectives: The goal of this study was to evaluate the accuracy of the 2013 ACC/AHA Pooled Cohort Risk Equation within a large, multiethnic population in clinical care.Methods: The target population for consideration of cholesterol-lowering therapy in a large, integrated health care delivery system population was identified in 2008 and followed up through 2013. The main analyses excluded those with known ASCVD, diabetes mellitus, low-density lipoprotein cholesterol levels <70 or ≥190 mg/dl, prior lipid-lowering therapy use, or incomplete 5-year follow-up. Patient characteristics were obtained from electronic medical records, and ASCVD events were ascertained by using validated algorithms for hospitalization databases and death certificates. We compared predicted versus observed 5-year ASCVD risk, overall and according to sex and race/ethnicity. We additionally examined predicted versus observed risk in patients with diabetes mellitus.Results: Among 307,591 eligible adults without diabetes between 40 and 75 years of age, 22,283 were black, 52,917 were Asian/Pacific Islander, and 18,745 were Hispanic. We observed 2,061 ASCVD events during 1,515,142 person-years. In each 5-year predicted ASCVD risk category, observed 5-year ASCVD risk was substantially lower: 0.20% for predicted risk <2.50%; 0.65% for predicted risk 2.50% to <3.75%; 0.90% for predicted risk 3.75% to <5.00%; and 1.85% for predicted risk ≥5.00% (C statistic: 0.74). Similar ASCVD risk overestimation and poor calibration with moderate discrimination (C statistic: 0.68 to 0.74) were observed in sex, racial/ethnic, and socioeconomic status subgroups, and in sensitivity analyses among patients receiving statins for primary prevention. Calibration among 4,242 eligible adults with diabetes was improved, but discrimination was worse (C statistic: 0.64).Conclusions: In a large, contemporary "real-world" population, the ACC/AHA Pooled Cohort Risk Equation substantially overestimated actual 5-year risk in adults without diabetes, overall and across sociodemographic subgroups. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
3. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity.
- Author
-
Tisminetzky, Mayra, Gurwitz, Jerry H., Tabada, Grace, Reynolds, Kristi, Fortmann, Stephen P., Garcia, Elisha, Pham, Thu, Goldberg, Robert, and Go, Alan S.
- Subjects
- *
HEART failure , *ANGIOTENSIN-receptor blockers , *ACE inhibitors , *COMORBIDITY , *INTEGRATED health care delivery , *ACUTE kidney failure - Abstract
Background: Current clinical practice guidelines recommend routine kidney function and serum potassium testing within 30 days of initiating angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy. However, evidence is lacking on whether routine follow-up testing reduces therapy-related adverse events in adults with heart failure and if multimorbidity influences the association between laboratory testing and these adverse events.Methods: We conducted a retrospective cohort study among adults with heart failure from 4 US integrated health care delivery systems. Multimorbidity was defined using counts of chronic conditions. Patients with outpatient serum creatinine and potassium tests in the 30 days after starting ACEI or ARB therapy were matched 1:1 to patients without follow-up tests. We evaluated the association of follow-up testing with 30-day all-cause mortality and hospitalization with acute kidney injury or hyperkalemia using Cox regression.Results: We identified 3629 matched adults with heart failure initiating ACEI or ARB therapy between January 1, 2005, and December 31, 2012. Follow-up testing was not significantly associated with 30-day all-cause mortality (adjusted hazard ratio [aHR] 0.45, 95% confidence interval [CI] 0.14; 1.39) and hospitalization with hyperkalemia (aHR 0.73, 95% CI, 0.33; 1.61). However, follow-up testing was significantly associated with hospitalization with acute kidney injury (aHR, 1.40, 95% CI, 1.01; 1.94). Interaction between multimorbidity burden and follow-up testing was not statistically significant in any of the outcome models examined.Conclusions: Routine laboratory monitoring after ACEI or ARB therapy initiation was not associated with risk of 30-day all-cause mortality or hospitalization with hyperkalemia across the spectrum of multimorbidity burden in a cohort of patients with heart failure. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. NATURAL HISTORY OF AORTIC STENOSIS IN A LARGE INTEGRATED HEALTH CARE DELIVERY SYSTEM.
- Author
-
Solomon, Matthew D., Tabada, Grace, Allen, Amanda, Sung, Sue Hee, and Go, Alan S.
- Subjects
- *
INTEGRATED health care delivery , *AORTIC stenosis , *NATURAL history , *HEART valve diseases - Published
- 2020
- Full Text
- View/download PDF
5. COVID-19 and Risk of VTE in Ethnically Diverse Populations.
- Author
-
Go, Alan S., Reynolds, Kristi, Tabada, Grace H., Prasad, Priya A., Sung, Sue Hee, Garcia, Elisha, Portugal, Cecilia, Fan, Dongjie, Pai, Ashok P., and Fang, Margaret C.
- Abstract
Background: Limited existing data suggest that the novel COVID-19 may increase risk of VTE, but information from large, ethnically diverse populations with appropriate control participants is lacking.Research Question: Does the rate of VTE among adults hospitalized with COVID-19 differ from matched hospitalized control participants without COVID-19?Study Design and Methods: We conducted a retrospective study among hospitalized adults with laboratory-confirmed COVID-19 and hospitalized adults without evidence of COVID-19 matched for age, sex, race or ethnicity, acute illness severity, and month of hospitalization between February 2020 and August 2020 from two integrated health-care delivery systems with 36 hospitals. Outcomes included VTE (DVT or pulmonary embolism ascertained using diagnosis codes combined with validated natural language processing algorithms applied to electronic health records) and death resulting from any cause at 30 days. Fine and Gray hazards regression was performed to evaluate the association of COVID-19 with VTE after accounting for competing risk of death and residual differences between groups, as well as to identify predictors of VTE in patients with COVID-19.Results: We identified 6,319 adults with COVID-19 and 6,319 matched adults without COVID-19, with mean ± SD age of 60.0 ± 17.2 years, 46% women, 53.1% Hispanic, 14.6% Asian/Pacific Islander, and 10.3% Black. During 30-day follow-up, 313 validated cases of VTE (160 COVID-19, 153 control participants) and 1,172 deaths (817 in patients with COVID-19, 355 in control participants) occurred. Adults with COVID-19 showed a more than threefold adjusted risk of VTE (adjusted hazard ratio, 3.48; 95% CI, 2.03-5.98) compared with matched control participants. Predictors of VTE in patients with COVID-19 included age ≥ 55 years, Black race, prior VTE, diagnosed sepsis, prior moderate or severe liver disease, BMI ≥ 40 kg/m2, and platelet count > 217 k/μL.Interpretation: Among ethnically diverse hospitalized adults, COVID-19 infection increased the risk of VTE, and selected patient characteristics were associated with higher thromboembolic risk in the setting of COVID-19. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. RE-EVALUATION OF RACE AND ETHNICITY WITH ADVERSE OUTCOMES IN HEART FAILURE.
- Author
-
Savitz, Samuel T., Tabada, Grace H., Sung, Sue Hee, Leong, Thomas, Lee, Keane, Rana, Jamal, and Go, Alan S.
- Subjects
- *
HEART failure - Published
- 2019
- Full Text
- View/download PDF
7. Abstract 12623: A New ASCVD Risk Estimator is More Accurate Than the ACC/AHA Pooled Cohort Equation in Four Diverse Community-Based Populations in the U.S. and Canada.
- Author
-
Go, Alan S, Tabada, Grace, Reynolds, Kristi, Fortmann, Stephen P, Garg, Amit, Scott, Ronald D, Young, Joseph, Lo, Joan C, Solomon, Matthew D, Wei, Rong, Allison, Michael J, McArthur, Eric, Nash, Danielle M, Sung, Sue Hee, and Rana, Jamal S
- Subjects
- *
ELECTRONIC health records , *DEATH certificates , *ELECTRONIC systems , *TREATMENT of diabetes - Abstract
Introduction: The Kaiser Permanente ASCVD Risk Estimator (KPARE) was developed to address the systematic overestimation of actual ASCVD risk by the ACC/AHA ASCVD Pooled Cohort Equation (ACC/AHA PCE) in contemporary populations. We evaluated the accuracy and generalizability of KPARE for estimating 10-year ASCVD risk in eligible primary prevention, community-based populations in the U.S. and Canada, as compared with the ACC/AHA PCE. Methods: We identified adults 40-79 years old in 3 contemporary U.S. populations (Kaiser Permanente Northern California (KPNC), Southern California (KPSC) and Northwest (KPNW), as well as adults 66-79 years old in Ontario, Canada who had LDL-C 70-189 mg/dL, no known ASCVD, diabetes or lipid-lowering therapy and had complete follow-up. Non-fatal and fatal ASCVD events were ascertained from health system electronic health records and death certificates using validated algorithms. We examined observed ASCVD event rates within deciles of predicted 10-year risk using the KPARE vs. the ACC/AHA PCE predicted risk, and calculated metrics of discrimination and calibration. Results: In eligible primary prevention validation cohorts of KPNC (N=151,409), KPSC (N=246,815), KPNW (N=46,784), and Ontario, Canada (N=60,612 adults), the KPARE showed both better discrimination and calibration (Figure) compared to the ACC/AHA PCE to predict 10-year risk of ASCVD events, with c-statistics of 0.78, 0.78, 0.79, and 0.65, respectively. Categorical net reclassification index showed the KPARE improved ASCVD risk prediction over the ACC/AHA PCE by 23% in the KPNC validation cohort, 24% in KPSC, 33% in KPNW, and 25% in Ontario, Canada. Results were similar when stratified by race-gender subgroups. Conclusions: The new Kaiser Permanente ASCVD Risk Estimator provides more accurate ASCVD risk estimates in various community populations than the ACC/AHA PCE and may provide greater utility in shared decision-making for primary prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
8. A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia.
- Author
-
Ambrosy, Andrew P., Fitzpatrick, Jesse K., Tabada, Grace H., Gurwitz, Jerry H., Artz, Andrew, Schrier, Stanley L., Rao, Sunil V., Reynolds, Kristi, Smith, David H., Peterson, Pamela N., Fortmann, Stephen P., Sung, Sue Hee, Cohen, Harvey Jay, and Go, Alan S.
- Subjects
- *
OLDER people , *HEART failure , *ANEMIA , *ELECTRONIC health records , *IRON deficiency , *FERRITIN - Abstract
Low transferrin saturation (TSAT) or reduced serum ferritin level are suggestive of iron deficiency but the relationship between iron parameters and outcomes has not been systematically evaluated in older adults with heart failure (HF) and anemia. We identified a multicenter cohort of adults age ≥ 65 years with HF and incident anemia (hemoglobin <13 g/dL [men] or < 12 g/dL [women]) between 2005 and 2012. Patients were included if ferritin (ng/mL) and TSAT (%) were evaluated within 90 days of incident anemia. HF hospitalizations and all-cause death were ascertained from electronic health records. Among 4103 older adults with HF and incident anemia, 47% had TSAT <20% and the median (IQR) ferritin was 126 (53, 256) ng/mL. In multivariable analyses, compared with TSAT ≥20%, patients with TSAT <20% were at increased risk of HF hospitalization for serum ferritin <100 ng/mL (adjusted HR [aHR] 1.40, 95% CI:1.16–1.70) and 100–300 ng/mL (aHR 1.24, 95% CI:1.01–1.52) but not for a ferritin >300 ng/mL (aHR 0.89, 95% CI 0.65–1.23). In addition, TSAT <20% was independently associated with an increased risk of all-cause death regardless of serum ferritin level (<100 ng/mL: aHR 1.42, 95% CI:1.20–1.68; 100–300 ng/mL: aHR 1.18, 95% CI:1.00–1.38; >300 ng/mL: aHR 1.33, 95% CI:1.06–1.69). Among older adults with HF and incident anemia who had iron studies tested, nearly half had a TSAT <20%, which was independently associated with higher rates of morbidity and death. • Among older adults with HF, ~55% of patients were found to have iron deficiency (i.e., ferritin <100 ng/mL or ferritin 100–300 ng/mL and TSAT <20%). • A TSAT <20% was independently associated with HF hospitalizations and all-cause death. • These findings remained unchanged in sensitivity analyses stratified by degree of systolic dysfunction (i.e., reduced vs. mid-range vs. preserved). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. LEVELS OF OBESITY AND ACCURACY OF THE ATHEROSCLEROTIC CARDIOVASCULAR RISK EQUATION IN A LARGE COMMUNITY-BASED COHORT.
- Author
-
Rana, Jamal S., Tabada, Grace H., Solomon, Matthew, Lo, Joan C., Jaffe, Marc, Sung, Sue Hee, and Go, Alan S.
- Subjects
- *
OBESITY , *EQUATIONS , *RISK - Published
- 2017
- Full Text
- View/download PDF
10. Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter‐Defibrillator Therapies.
- Author
-
Hajduk, Alexandra M., Gurwitz, Jerry H., Tabada, Grace, Masoudi, Frederick A., Magid, David J., Greenlee, Robert T., Sung, Sue Hee, Cassidy‐Bushrow, Andrea E., Liu, Taylor I., Reynolds, Kristi, Smith, David H., Fiocchi, Frances, Goldberg, Robert, Gill, Thomas M., Gupta, Nigel, Peterson, Pamela N., Schuger, Claudio, Vidaillet, Humberto, Hammill, Stephen C., and Allore, Heather
- Subjects
- *
IMPLANTABLE cardioverter-defibrillators , *COMORBIDITY , *DISEASE risk factors , *CHRONIC disease treatment , *TREATMENT effectiveness , *CARDIAC pacing , *CHRONIC diseases , *LEFT heart ventricle , *RISK assessment , *SHOCK (Pathology) , *VENTRICULAR tachycardia , *RELATIVE medical risk , *DISEASE complications ,CARDIAC arrest prevention - Abstract
OBJECTIVE: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN: Retrospective cohort study. SETTING: Seven US healthcare delivery systems. PARTICIPANTS: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter‐defibrillator (ICD) for primary prevention. MEASUREMENTS: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0‐3, 4‐5, 6‐7 and 8‐16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4‐8), with 98% having at least two comorbidities. During a mean 2.2 years of follow‐up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14‐3.31] for 4‐5 comorbidities; HR = 2.25 [95% CI = 1.25‐4.05] for 6‐7 comorbidities; and HR = 2.91 [95% CI = 1.54‐5.50] for 8‐16 comorbidities). Participants with 8‐16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43‐3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67‐6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07‐2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. QUANTITATIVE AORTIC STENOSIS PARAMETERS AND LONG-TERM OUTCOMES: RESULTS FROM THE KP-VALVE PROJECT.
- Author
-
Solomon, Matthew D., Go, Alan S., Tabada, Grace, Allen, Amanda, Garcia, Elisha, Philip, Femi, DeMaria, Anthony N., and Lee, Catherine
- Subjects
- *
AORTIC stenosis - Published
- 2023
- Full Text
- View/download PDF
12. COPD Comorbidity Profiles and 2-Year Trajectory of Acute and Postacute Care Use.
- Author
-
Shen, Ernest, Lee, Janet S., Mularski, Richard A., Crawford, Phillip, Go, Alan S., Sung, Sue H., Tabada, Grace H., Gould, Michael K., and Nguyen, Huong Q.
- Subjects
- *
INTEGRATED health care delivery , *COMORBIDITY , *OBSTRUCTIVE lung diseases , *MEDICAL care use , *ELECTRONIC health records , *OBSTRUCTIVE lung disease treatment , *RESEARCH , *TERMINAL care , *TIME , *RESEARCH methodology , *RETROSPECTIVE studies , *MEDICAL cooperation , *EVALUATION research , *SUBACUTE care , *COMPARATIVE studies , *QUESTIONNAIRES , *LONGITUDINAL method - Abstract
Background: Multiple morbidity is the norm in advanced COPD and contributes to high symptom burden and worse outcomes.Research Question: Can distinct comorbidity profiles be identified and validated in a community-based sample of patients with COPD from a large integrated health care system using a standard, commonly used diagnostic code-based comorbidity index and downstream 2-year health care use data?Study Design and Methods: In this retrospective cohort study, we used latent class analysis (LCA) to identify comorbidity profiles in a population-based sample of 91,453 patients with a COPD diagnosis between 2011 and 2015. We included specific comorbid conditions from the Charlson Comorbidity Index (CCI) and accounted for variation in underlying prevalence of different comorbidities across the three study sites. Sociodemographic, clinical, and health-care use data were obtained from electronic health records (EHRs). Multivariate logistic regression analysis was used to compare rates of acute and postacute care use by class.Results: The mean age was 71 ± 11 years, 55% of patients were women, 23% of patients were people of color, and 80% of patients were former or current smokers. LCA identified four distinct comorbidity profiles with progressively higher CCI scores: low morbidity (61%; 1.9 ± 1.4), metabolic renal (21%; 4.7 ± 1.8), cardiovascular (12%; 4.6 ± 1.9), and multimorbidity (7%; 7.5 ± 1.7). In multivariate models, during 2 years of follow-up, a significant, nonoverlapping increase was found in the odds of having any all-cause acute (hospitalizations, observation stays, and ED visits) and postacute care use across the comorbidity profiles.Interpretation: Distinct comorbidity profiles can be identified in patients with COPD using standard EHR-based diagnostic codes, and these profiles are associated with subsequent acute and postacute care use. Population-based risk stratification schemes for end-to-end, comprehensive COPD management should consider integrating comorbidity profiles such as those found in this study. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
- Author
-
Budayr, Amer, Tan, Thida C., Lo, Joan C., Zaroff, Jonathan G., Tabada, Grace H., Yang, Jingrong, and Go, Alan S.
- Subjects
- *
AGE distribution , *BROMOCRIPTINE , *COMBINATION drug therapy , *CONFIDENCE intervals , *ECHOCARDIOGRAPHY , *ERGOT alkaloids , *HEART valves , *HEART valve diseases , *PITUITARY diseases , *RISK assessment , *SEX distribution , *TREATMENT effectiveness , *DISEASE prevalence , *CROSS-sectional method , *TREATMENT duration , *ODDS ratio , *DISEASE risk factors - Abstract
Background: Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists. Methods: This cross-sectional study was conducted among adults receiving cabergoline or bromocriptine for > 12 months for hyperprolactinemia and had no cardiac-related symptoms. Cardiac valve morphology and function were assessed from transthoracic echocardiograms at the study visit (except for two participants) with evaluation performed blinded to type and duration of dopamine agonist received. Results: Among 174 participants (mean age 49 ± 13 years, 63% women) without known structural heart disease before starting therapy, 62 received only cabergoline, 63 received only bromocriptine, and 49 received both. Median cabergoline use was 2.8 years in cabergoline only users and 3.2 years for those exposed to both cabergoline and bromocriptine; median bromocriptine use was 5.5 years in bromocriptine only users and 1.1 years for those exposed to both cabergoline and bromocriptine. Compared with bromocriptine only users (17.5%), regurgitation of ≥1 valve was more common for cabergoline only (37.1%, P = 0.02) but not for combined exposure (26.5%, P = 0.26). Compared with bromocriptine only exposure (1.6%), regurgitation of ≥2 valves was more common for cabergoline only (11.3%, P = 0.03) and combined exposure (12.2%, P = 0.04). Cabergoline only users had higher age-sex-adjusted odds for ≥1 valve with grade 2+ regurgitation compared to bromocriptine only users (adjusted odds ratio [aOR] 3.2, 95% confidence interval [CI]:1.3–7.5, P = 0.008), but the association for combined exposure to cabergoline and bromocriptine was not significant (aOR 1.7, 95%CI:0.7–4.3, P = 0.26). Compared to bromocriptine only, age-sex-adjusted odds of ≥2 valves with grade 2+ regurgitation were higher for both cabergoline only (aOR 8.4, 95% CI:1.0–72.2, P = 0.05) and combined exposure (aOR 8.8, 95% CI:1.0–75.8, P = 0.05). Cumulative cabergoline exposure > 115 mg was associated with a higher age-sex adjusted odds of ≥2 valves with grade 2+ regurgitation (aOR 9.6, 95%CI:1.1–81.3, P = 0.04) compared to bromocriptine only. Conclusions: Among community-based adults treated for hyperprolactinemia, cabergoline use and greater cumulative cabergoline exposure were associated with a higher prevalence of primarily mild valvular regurgitation compared with bromocriptine. Research is needed to clarify which patients treated with dopamine agonists may benefit from echocardiographic screening and surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease.
- Author
-
Gurwitz, Jerry H., Magid, David J., Smith, David H., Tabada, Grace H., Sung, Sue Hee, Allen, Larry A., McManus, David D., Goldberg, Robert J., Tisminetzky, Mayra, and Go, Alan S.
- Subjects
- *
TREATMENT effectiveness , *HEART failure treatment , *ADRENERGIC beta blockers , *LUNG disease treatment , *ACE inhibitors , *CHRONIC kidney failure , *COMORBIDITY , *ANGIOTENSIN-receptor blockers , *PATIENTS , *THERAPEUTICS , *CONFIDENCE intervals , *GLOMERULAR filtration rate , *HEART failure , *HOSPITAL care , *LUNG diseases , *MORTALITY , *PROBABILITY theory , *RELATIVE medical risk , *RETROSPECTIVE studies , *ANGIOTENSIN receptors , *DESCRIPTIVE statistics , *VENTRICULAR ejection fraction , *DISEASE complications - Abstract
Objectives To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure ( HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors ( ACE-Is) and angiotensin II receptor blockers ( ARBs) in individuals with HF and chronic kidney disease. Design Retrospective cohort study. Setting Community. Participants Individuals with HF with reduced ejection fraction ( HFr EF) or HF with preserved ejection fraction ( HFp EF). Methods We undertook separate new-user cohort studies to assess the effectiveness of beta-blocker therapy in treating HF and chronic lung disease and ACE-Is and ARBs in treating HF and chronic kidney disease ( CKD). Individuals with a chronic lung disease diagnosis were included in the group with HF and chronic lung disease ( International Classification of Diseases, Ninth Revision, codes 490-496, 518). Individuals with an estimated glomerular filtration rate less than 60 mL/min per 1.73 m2 were included in the group with HF and CKD. The clinical outcomes of interest were death from any cause, hospitalization for HF, and hospitalization for any reason. We fitted pooled logistic marginal structural models using inverse probability weighting, stratified according to HF type. Results For individuals with HFr EF with chronic lung disease, beta-blocker therapy was protective against death (relative risk ( RR) = 0.58, 95% confidence interval ( CI) = 0.44-0.77) and hospitalization for HF ( RR = 0.78, 95% CI = 0.60-1.00). For those with HFp EF, no statistically significant associations between beta-blocker therapy use and any of the outcomes were observed. We found ACE-I and ARB use to be protective against all three outcomes of interest in individuals with HFr EF (death from any cause: RR = 0.60, 95% 0.40-0.91; hospitalization for HF: RR = 0.43, 95% CI = 0.28-0.67; hospitalization for any reason: RR = 0.63, 95% CI = 0.45-0.89, respectively) and those with HFp EF (death from any cause: RR = 0.52, 95% CI = 0.33-0.81; hospitalization for HF: RR = 0.35, 95% CI = 0.18-0.68; hospitalization for any reason: RR = 0.67, 95% CI = 0.47-0.95). Conclusion Large observational studies may allow for identification of important subgroups of individuals with HF that might benefit from existing treatment approaches. Our findings may also better inform the design of more-definitive future observational studies and randomized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.